Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

The study highlighted the significant benefits of long-term oxygen therapy in reducing total and hospitalized acute ...

Cardiopulmonary risk has recently been proposed and is defined as: The risk of serious and/or cardiovascular events in ...

Learn more about supplements for lung health, including vitamins, minerals, and herbs that support breathing, reduce ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

COPD is a chronic respiratory disease that damages the lungs and causes progressive lung function ... and economic burden due to recurrent acute exacerbations that require systemic corticosteroid ...

COPD is a chronic respiratory disease that damages the lungs and causes progressive lung function decline and is the fourth leading ... COPD is also associated with a significant health and economic ...

IL-5 is a key cytokine (protein) in type 2 inflammation which is an underlying driver in many diseases. This type of inflammation is detected in up to 40% of patients with COPD and is a major cause of ...

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary disease ...